Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Treasury Shares (2020 - 2024)

Historic Treasury Shares for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q4 2024 value amounting to $4.0 million.

  • Apellis Pharmaceuticals' Treasury Shares fell 790.51% to $4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.0 million, marking a year-over-year decrease of 790.51%. This contributed to the annual value of $4.0 million for FY2024, which is 790.51% down from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Treasury Shares stood at $4.0 million for Q4 2024, which was down 790.51% from $4.3 million recorded in Q4 2023.
  • Apellis Pharmaceuticals' 5-year Treasury Shares high stood at $4.3 million for Q4 2023, and its period low was $502000.0 during Q4 2020.
  • Its 5-year average for Treasury Shares is $2.7 million, with a median of $3.6 million in 2022.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Treasury Shares skyrocketed by 19159.18% in 2022 and then crashed by 790.51% in 2024.
  • Over the past 5 years, Apellis Pharmaceuticals' Treasury Shares (Quarter) stood at $502000.0 in 2020, then skyrocketed by 144.02% to $1.2 million in 2021, then skyrocketed by 191.59% to $3.6 million in 2022, then rose by 20.41% to $4.3 million in 2023, then dropped by 7.91% to $4.0 million in 2024.
  • Its Treasury Shares was $4.0 million in Q4 2024, compared to $4.3 million in Q4 2023 and $3.6 million in Q4 2022.